living cell technologies™

**Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need.**

## The business

- Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of its two lead products.
- LCT retains a 50% share of any future profits from its two lead products.
- LCT retains a perpetual exclusive licence to continue to develop products using intellectual property held outside the joint venture.
- LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.



## Product pipeline and key milestones

- LCT currently has two products in clinical development: DIABECELL® for type 1 diabetes and NTCELL® for Parkinson's disease.
- DIABECELL is in late stage clinical trials and is on track to be commercially available in 2016.
- LCT aims to have three products in the market by 2020.



## Financial information

### DIABECELL partnership

- In 2011, LCT formed an A$50m partnership with OPF, establishing the joint venture Diatranz Otsuka Limited NZ (DOL).
- LCT transferred DIABECELL IP into the DOL joint venture.
- OPF invested A$25m to fund the ongoing development of DIABECELL.

### NTCELL partnership

- In 2012, LCT and OPF agreed to co-develop NTCELL for Parkinson's disease.
- OPF will fund the upcoming Phase I trial of NTCELL in Parkinson's disease in New Zealand.
- If the upcoming Phase I trial is successful, LCT will transfer NTCELL IP into the DOL joint venture and OPF will invest an additional A$20 million to fund further clinical development of NTCELL.

### New Zealand investment

- LCT has 66 employees at three sites across New Zealand.
- At 31 December 2012, LCT has raised approximately A$67 million from investors, of which approximately A$57 million has been applied in New Zealand.
- LCT has also received New Zealand Government grants totalling A$6 million approximately.
- The DOL joint venture has attracted an additional A$25m cash investment into New Zealand.
- As DIABECELL and NTCELL achieve development milestones, there is the potential for more than A$20 million more investment into New Zealand over the next two years.



## The science

- LCT's product pipeline consists of cell therapies developed from cells sourced from its unique herd of virus-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands.
- LCT's unique proprietary technology, IMMUPEL™, coats cells with protective capsules that prevent them from attack by the patient's immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.
- IMMUPEL technology has potential applications across the medical spectrum, including type 1 diabetes, Parkinson's disease, stroke, Huntington's disease, hearing loss and wound healing.

## DIABECELL


- DIABECELL is a breakthrough cell therapy in late-stage clinical trials that has the potential to be life changing for the millions of people with type 1 diabetes.

### The need

- Estimated number of adults who suffer from type 1 diabetes:

| | |
|---|---|
| New Zealand | 17,000 |
| Australia | 77,000 |
| Worldwide | 8,000,000 |

- Type 1 diabetes usually requires life-long treatment with regular insulin injections.
- The current total market worldwide for injected insulin for type 1 diabetes is approximately A$2 billion p.a.
- Up to 15% of people with type 1 diabetes cannot keep their blood glucose within safe levels using standard treatment and are at particular risk of sudden and unaware hypoglycaemia – when their blood glucose falls to dangerous levels without any sign or symptom that this is happening.

### The product

- DIABECELL contains porcine insulin-producing cells, which when transplanted into the patient's body, begin to secrete insulin in response to rises in glucose.
- In clinical trials in people with type 1 diabetes, DIABECELL has been shown to:
  - significantly reduce unaware hypoglycaemia.
  - reduce the amount of insulin that patients need to inject.
  - improve overall glucose control, as shown by stabilisation or a decrease in HbA1c.

## NTCELL

- NTCELL is a unique cell therapy with exciting preclinical results that demonstrate it can regenerate damaged tissue.
- NTCELL is initially being developed to offer people with Parkinson's disease the hope of being able to halt disease progression and restore quality of life.

### The need

- Estimated number of people who suffer from Parkinson's disease:

| | |
|---|---|
| New Zealand | 10,000 |
| Australia | 64,000 |
| Worldwide | 4,000,000 |

- The global market for the current standard treatment for Parkinson's disease – dopamine replacement – is approximately A$2 billion p.a.

### The product

- NTCELL has shown a powerful ability to regenerate tissue and restore function in animal models of Parkinson's disease, stroke, Huntington's disease, hearing loss and other non-neurological conditions, such as wound healing.
- NTCELL is in Phase I clinical trials in New Zealand for Parkinson's disease.

For more information visit **www.lctglobal.com** or follow **@lctglobal** on Twitter.